Lomitapide affects HDL composition and function

Angelo Baldassare Cefalu', Maurizio Averna, Adorni, Verhoeven, Angelo B. Cefalù, Yahya, Eric J.G. Sijbrands, Roeters Van Lennep, Favari, Sijbrands, Laura Calabresi, Bernini, Maurizio R. Averna, Mulder, Monica Gomaraschi, Zimetti

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Background: Lomitapide reduces low-density lipoprotein-cholesterol (LDL-C) but also high-density lipoprotein-cholesterol (HDL-C) levels. The latter may reduce the clinical efficacy of lomitapide. We investigated the effect of lomitapide on HDL-C levels and on cholesterol efflux capacity (CEC) of HDL in patients with homozygous familial hypercholesterolemia (HoFH). Methods and results: Four HoFH patients were treated with increasing dosages of lomitapide. Lomitapide decreased LDL-C (range -34 to -89%). Total HDL-C levels decreased (range -16 to -34%) with a shift to buoyant HDL. ABCA1-mediated CEC decreased in all patients (range -39 to -99%). The changes of total, ABCG1- and SR-BI-mediated CEC were less consistent. Conclusion: Lomitapide decreased LDL-C and HDL-C levels. Our report raises the hypothesis that the anti-atherogenic potential of HDL seems to be unaffected as total CEC did not seem to change consistently. Combined with the reduction of atherogenic lipoproteins, the net effect of lomitapide appears to be beneficial in HoFH patients.
Original languageEnglish
Pages (from-to)15-18
Number of pages4
Publication statusPublished - 2016

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Lomitapide affects HDL composition and function'. Together they form a unique fingerprint.

Cite this